Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men.

Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, Maecke HR, Reubi JC, Weber WA.

Theranostics. 2014 Feb 1;4(4):412-9. doi: 10.7150/thno.7324. eCollection 2014.

2.

Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.

Chatalic KL, Franssen GM, van Weerden WM, McBride WJ, Laverman P, de Blois E, Hajjaj B, Brunel L, Goldenberg DM, Fehrentz JA, Martinez J, Boerman OC, de Jong M.

J Nucl Med. 2014 Dec;55(12):2050-6. doi: 10.2967/jnumed.114.141143. Epub 2014 Nov 20.

3.

Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.

Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F, Nicolas G, Cescato R, Reubi JC, Maecke HR.

J Nucl Med. 2011 Dec;52(12):1970-8. doi: 10.2967/jnumed.111.094375. Epub 2011 Nov 11.

4.

A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.

Durkan K, Jiang Z, Rold TL, Sieckman GL, Hoffman TJ, Bandari RP, Szczodroski AF, Liu L, Miao Y, Reynolds TS, Smith CJ.

Nucl Med Biol. 2014 Feb;41(2):133-9. doi: 10.1016/j.nucmedbio.2013.11.006. Epub 2013 Nov 28.

5.

Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.

Maina T, Bergsma H, Kulkarni HR, Mueller D, Charalambidis D, Krenning EP, Nock BA, de Jong M, Baum RP.

Eur J Nucl Med Mol Imaging. 2016 May;43(5):964-73. doi: 10.1007/s00259-015-3232-1. Epub 2015 Dec 2.

PMID:
26631238
6.

Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.

Zhang H, Desai P, Koike Y, Houghton J, Carlin S, Tandon N, Touijer K, Weber WA.

J Nucl Med. 2017 Jan;58(1):29-35. doi: 10.2967/jnumed.116.176099. Epub 2016 Aug 11.

7.

Biological evaluation of (177)Lu-labeled DOTA-Ala(SO3H)-Aminooctanoyl-Gln-Trp-Ala-Val-N methyl Gly-His-Statine-Leu-NH2 for gastrin-releasing peptide receptor-positive prostate tumor targeting.

Lim JC, Cho EH, Kim JJ, Choi SM, Lee Sy, Nam SS, Park UJ, Park SH.

Nucl Med Biol. 2015 Feb;42(2):131-6. doi: 10.1016/j.nucmedbio.2014.10.007. Epub 2014 Oct 16.

PMID:
25457455
8.

N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.

Gourni E, Mansi R, Jamous M, Waser B, Smerling C, Burian A, Buchegger F, Reubi JC, Maecke HR.

J Nucl Med. 2014 Oct;55(10):1719-25. doi: 10.2967/jnumed.114.141242. Epub 2014 Aug 21.

9.

Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.

Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, Singh A, Krenning EP, de Jong M, Maina T, Baum RP.

J Nucl Med. 2017 Jan;58(1):75-80. doi: 10.2967/jnumed.116.178889. Epub 2016 Aug 4.

10.

Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging.

Varasteh Z, Velikyan I, Lindeberg G, Sörensen J, Larhed M, Sandström M, Selvaraju RK, Malmberg J, Tolmachev V, Orlova A.

Bioconjug Chem. 2013 Jul 17;24(7):1144-53. doi: 10.1021/bc300659k. Epub 2013 Jul 2.

PMID:
23763444
11.

In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging.

Varasteh Z, Aberg O, Velikyan I, Lindeberg G, Sörensen J, Larhed M, Antoni G, Sandström M, Tolmachev V, Orlova A.

PLoS One. 2013 Dec 3;8(12):e81932. doi: 10.1371/journal.pone.0081932. eCollection 2013.

12.

Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer.

Gourni E, Del Pozzo L, Kheirallah E, Smerling C, Waser B, Reubi JC, Paterson BM, Donnelly PS, Meyer PT, Maecke HR.

Mol Pharm. 2015 Aug 3;12(8):2781-90. doi: 10.1021/mp500671j. Epub 2015 Jul 15.

PMID:
26132879
13.

In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.

Garrison JC, Rold TL, Sieckman GL, Figueroa SD, Volkert WA, Jurisson SS, Hoffman TJ.

J Nucl Med. 2007 Aug;48(8):1327-37. Epub 2007 Jul 13.

14.

In vivo MR/optical imaging for gastrin releasing peptide receptor of prostate cancer tumor using Gd-TTDA-NP-BN-Cy5.5.

Lin YH, Dayananda K, Chen CY, Liu GC, Luo TY, Hsu HS, Wang YM.

Bioorg Med Chem. 2011 Feb 1;19(3):1085-96. doi: 10.1016/j.bmc.2010.04.040. Epub 2010 Apr 21.

PMID:
20493715
15.

Approaches to improve metabolic stability of a statine-based GRP receptor antagonist.

Popp I, Del Pozzo L, Waser B, Reubi JC, Meyer PT, Maecke HR, Gourni E.

Nucl Med Biol. 2017 Feb;45:22-29. doi: 10.1016/j.nucmedbio.2016.11.004. Epub 2016 Nov 4.

PMID:
27865999
16.

Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.

Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, Vasanawala S, Gambhir SS, Iagaru A.

J Nucl Med. 2016 Apr;57(4):557-62. doi: 10.2967/jnumed.115.168393. Epub 2015 Dec 10.

17.

64Cu-1,4,7-Triazacyclononane-1,4-diacetic acid-9-aminonanoic acid-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2.

Shan L.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2011 Jan 2 [updated 2011 Jan 25].

18.

64Cu-1,4,7-Triazacyclononane-1,4-diacetic acid-6-aminohexanoic acid-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2.

Shan L.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2011 Jan 2 [updated 2011 Jan 25].

19.

64Cu-1,4,7-Triazacyclononane-1,4-diacetic acid-para-aminobenzoic acid-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2.

Shan L.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2011 Jan 2 [updated 2011 Jan 25].

20.

Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14).

Biddlecombe GB, Rogers BE, de Visser M, Parry JJ, de Jong M, Erion JL, Lewis JS.

Bioconjug Chem. 2007 May-Jun;18(3):724-30. Epub 2007 Mar 23.

PMID:
17378600

Supplemental Content

Support Center